Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.

Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.

Item
http://www.wikidata.org/entity/Q38098931
Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy.PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.Management of hereditary medullary thyroid carcinoma.Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells.The molecular classification of hereditary endocrine diseases.Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing's syndrome in a medullary thyroid carcinoma patient.Environmental Enrichment Reverses Tyrosine Kinase Inhibitor-Mediated Impairment Through BDNF-TrkB Pathway.Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.
P2860

Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.

Item
http://www.wikidata.org/entity/Q38098931
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.
@en
type
label
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.
@en
prefLabel
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P698